Oppenheimer Cuts Boston Scientific (NYSE:BSX) Price Target to $85.00

Boston Scientific (NYSE:BSX) had its price target reduced by Oppenheimer from $90.00 to $85.00 in a research report released on Monday, MarketBeat Ratings reports. They currently have an outperform rating on the medical equipment provider’s stock.

A number of other research firms have also weighed in on BSX. Canaccord Genuity Group reduced their price objective on shares of Boston Scientific from $71.00 to $70.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research note on Thursday, May 28th. Truist Financial reduced their price target on Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. Piper Sandler reissued an “overweight” rating and set a $65.00 price target on shares of Boston Scientific in a research note on Friday, June 12th. Finally, Needham & Company LLC dropped their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Boston Scientific Trading Up 0.0%

BSX stock opened at $46.06 on Monday. Boston Scientific has a twelve month low of $42.20 and a twelve month high of $109.50. The stock has a market capitalization of $68.47 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 0.88 and a beta of 0.58. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm’s fifty day simple moving average is $46.57 and its two-hundred day simple moving average is $62.73.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter last year, the business earned $0.75 EPS. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts anticipate that Boston Scientific will post 3.35 earnings per share for the current year.

Boston Scientific announced that its board has initiated a stock repurchase plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 9,800 shares of company stock worth $554,012 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after buying an additional 1,436,550 shares during the period. State Street Corp grew its holdings in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors grew its holdings in Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after acquiring an additional 502,627 shares in the last quarter. Norges Bank purchased a new position in Boston Scientific during the 4th quarter valued at about $2,199,395,000. Finally, Morgan Stanley increased its position in Boston Scientific by 10.8% during the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock valued at $2,189,289,000 after purchasing an additional 2,246,308 shares during the period. 89.07% of the stock is owned by institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted EPS of $0.86, above the $0.83 consensus estimate, while revenue of $5.442 billion exceeded expectations of roughly $5.36 billion. Sales increased 7.5% year over year, led by 8.3% growth in Cardiovascular and strong international performance. Boston Scientific announces results for second quarter 2026
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase program and announced a $1.5 billion investment in MiRus, including an option to acquire its transcatheter aortic valve replacement business. These actions could support long-term growth and per-share results. Boston Scientific Q2 revenue rises to $5.442 billion
• Neutral Sentiment: Boston Scientific is beginning a global restructuring program expected to cost $700 million to $800 million through 2029, with anticipated headcount reductions and potential annual cost savings of about $500 million. Near-term charges may weigh on results, while savings could improve margins later. Boston Scientific expects headcount reductions amid restructuring initiative
• Negative Sentiment: The company reduced full-year 2026 adjusted EPS guidance to $3.28–$3.32 from $3.34–$3.41, below the approximately $3.36 consensus. Third-quarter EPS and revenue guidance also trail analyst expectations.
• Negative Sentiment: Management cited softer-than-expected Watchman demand, unexpected challenges in the heart-implant market and competition affecting the electrophysiology business. The lower outlook overshadowed the quarterly beat and raised concerns about growth execution. Boston Scientific trims annual profit forecast on softer Watchman device demand
• Negative Sentiment: Analysts responded by cutting price targets, including BTIG to $60 from $65, although it maintained a Buy rating. BTIG lowers Boston Scientific price target

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.